ورود
مقالات فارسیISIکنفرانسهاژورنالها

The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study

محل انتشار: مجله آریا آترواسکلروز، دوره: 13، شماره: 6
سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 160

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1504728

شناسه ملی سند علمی:

JR_RYA-13-6_004

تاریخ نمایه سازی: 2 شهریور 1401

چکیده مقاله:

BACKGROUND: The major aim of this study was evaluating the effect of atorvastatin treatment on thiobarbituric acid reactive substances (TBARS), ferric reducing the ability of plasma (FRAP), small dense low-density lipoprotein cholesterol (sdLDL) and lipid profile in coronary artery disease (CAD) patients.METHODS: This study was carried out on ۸۳ patients with angiographically proven coronary artery stenosis (۵۲ men and ۳۱ women) at Shahid Madani Hospital, Khorramabad, Iran, in ۲۰۱۵. The patients were divided into the ۳ groups. ۲۷ patients were classified statins consumption less than ۶ days, ۲۸ patients for ۶ to ۹۰ days, and ۲۸ patients for more than ۹۰ days. The level of sdLDL, lipid profile, TBARS and FRAP were assayed.RESULTS: FRAP levels of patients that received atorvastatin for more than ۹۰ days (۸۳۲ ± ۱۰۱) were significantly elevated (P = ۰.۰۱) compared to the patients received atorvastatin less than ۶ days (۶۸۸ ± ۷۵), whereas the levels of TBARS diminished significantly (P = ۰.۰۴). Also, the levels of total cholesterol (TC) and LDL-C were significantly decreased after ۳ months of atorvastatin receiving (۱۵۸ as compared to patients that consumed atorvastatin less than ۶ days), (P = ۰.۰۲ and ۰.۰۳, respectively). The level of sdLDL was slightly increased with long-time consumption of atorvastatin (۳۷ ± ۱۴) in patients in comparison with patients that received atorvastatin less than ۶ days (۳۲ ± ۱۵) (P = ۰.۰۶), but was not significant.CONCLUSION: The serum level of TBARS decreased and the serum level of FRAP increased in patients with long-time receiving atorvastatin. Therefore, atorvastatin contributes to the lowering oxidative stress in these patients. 

کلیدواژه ها:

Atorvastatin ، Coronary Artery Disease ، Oxidative Stress

نویسندگان

Gholamreza Shahsavari

Assistant Professor, Department of Clinical Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Amir Raoufi

Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Aram Toolabi

Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Nahid Hosseninejadmir

Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Hassan Ahmadvand

Professor, Herbal Medicine Research Center AND Department of Clinical Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Mehdi Safariebrahimsarabie

Young Researchers, Elite Club Yadegar-e-Imam Khomeini (RAH), Shahr-e-Rey Branch, Islamic Azad University, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. ...
  • Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its ...
  • Ahmadvand H, Mabuchi H, Nohara A, Kobayahi J, Kawashiri MA. ...
  • Ahmadvand H, Noori A, Dehnoo MG, Bagheri S, Cheraghi RA. ...
  • Berneis KK, Krauss RM. Metabolic origins and clinical significance of ...
  • Kwon SW, Yoon SJ, Kang TS, Kwon HM, Kim JH, ...
  • Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, ...
  • Singh N, Singh N, Kumar SS, Kumar SA, Kafle D, ...
  • Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense ...
  • Tian L, Li C, Liu Y, Chen Y, Fu M. ...
  • Domingos H, Cunha RV, Paniago AM, Souza AS, Rodrigues RL, ...
  • Huang YC, Chang PY, Hwang JS, Ning HC. Association of ...
  • Llurba E, Casals E, Dominguez C, Delgado J, Mercade I, ...
  • Gentile M, Panico S, Mattiello A, Ubaldi S, Iannuzzo G, ...
  • Nozue T, Michishita I, Ishibashi Y, Ito S, Iwaki T, ...
  • Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev ...
  • Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, ...
  • Davignon J, Jacob RF, Mason RP. The antioxidant effects of ...
  • Ahmadvand H, Tavafi M, Khosrowbeygi A, Shahsavari G, Hormozi M, ...
  • Bolanos de la Torre AA, Henderson T, Nigam PS, Owusu-Apenten ...
  • Hirano T, Ito Y, Saegusa H, Yoshino G. A novel ...
  • Ahmadvand H, Ghasemi-Dehnoo M. Antiatherogenic, hepatoprotective, and hypolipidemic effects of ...
  • Pandey KB, Rizvi SI. Biomarkers of oxidative stress in red ...
  • Ahmadvand H, Tavafi M, Khosrowbeygi A. Amelioration of altered antioxidant ...
  • Majsterek I, Malinowska K, Stanczyk M, Kowalski M, Blaszczyk J, ...
  • Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect ...
  • Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, ...
  • Tavridou A, Efthimiadis A, Efthimiadis I, Paschalidou H. Antioxidant effects ...
  • Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, ...
  • Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, ...
  • Yoshino G, Nakano S, Matsumoto T, Murakami E, Morita T, ...
  • Nozue T, Michishita I, Ito Y, Hirano T. Effects of ...
  • Hosseini Gohari L, Karimzadeh Ghassab R, Firoozray M, Zavarehee A, ...
  • St-Pierre AC, Bergeron J, Pirro M, Cantin B, Dagenais GR, ...
  • Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, ...
  • Koh KK, Lim S, Choi H, Lee Y, Han SH, ...
  • Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary ...
    • نمایش کامل مراجع